Toxicology

#Academic #ADME / Tox #Analysis #Assay development optimisation & technology #Automation / robotics #Biochemistry #Business #Cell / tissue culture #Cell culture #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomes #High Content Screening #High throughput screening #Imaging #In Silico Biology #Lead discovery #Lead optimisation #Medicinal chemistry #PCR #Pharmacology #Preclinical #Regulatory #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Toxicology

Growing Interest in Outsourcing Ion Channel Services

Growing Interest in Outsourcing Ion Channel Services By Dr John Comley Summer 2008 Significant demand now exists in Pharma and Biotech to access ion channel testing services and this is reflected by the number and the variety of service offerings. In the highly competitive area of cardiac safety hERG testing… Read More

#Archive

#Academic #ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biomarkers #Business #Cell / tissue culture #Cell culture #Cellular & Molecular biology #Cellular assays #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomes #High Content Screening #High throughput screening #Imaging #Lead discovery #Lead optimisation #Orphan drugs #PCR #Preclinical #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Toxicology

Progress in the Implementation of Label-Free Detection – Cell-based assays

Progress in the Implementation of Label-Free Detection - Cell-based assays By Dr John Comley Progress made in the use of impedance and optical grating technologies for label-free detection of cell-based assays where examined in HTStec's recent Cell-Based Label-Free Detection Trends report. Uniquely all of these label-free offerings are plate-based and… Read More

#Archive

#Analysis #Assay development optimisation & technology #Biochemistry #Business #Cell therapy #Cellular & Molecular biology #Cellular assays #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Isotope labelling #Lead discovery #Oncology #PCR #Pharmacology #Pharmokinetics #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Target validation #Therapeutics #Toxicology

Screening the Human Kinome – Expectations Met or Promises Pending?

Screening the Human Kinome - Expectations Met or Promises Pending? By Dr Richard M. Eglen Protein kinases are important targets in drug discovery programmes aimed at treating cancer, autoimmune disorders, diabetes and neurological disorders. Novel information on kinase biology is opening up other approaches in the design of selective inhibitors… Read More

#Archive

HIV
#Analysis #Cell therapy #Cellular assays #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Lead discovery #RNA #Screening #Stem cells #Toxicology

HIV Therapy – Past, Present and Future

HIV Therapy - Past, Present and Future By Dr Laura Waters Since the identification of HIV in 1983 and licensing of AZT in 1986 we now have more than 20 agents available for HIV treatment from five drug classes. This article will review recent advances in HIV treatment and discuss… Read More

#Archive

#Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #High Content Screening #Immunology #Lead discovery #Medicinal chemistry #Orphan drugs #Pathology #Pharmacology #Protein chemistry / Proteomics #RNA #Therapeutics #Toxicology

Is Amyloid-related Toxicity an Inevitable Consequence of Ageing?

Is Amyloid-related Toxicity an Inevitable Consequence of Ageing? By Dr J Mark Treherne and Dr David IC Scopes Amyloid-related toxicity need not necessarily be the inevitable consequence of ageing, if some of the new drug discovery strategies to treat neurodegenerative and other ageing-related diseases succeed in the clinic. An increasing… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Business #Cell culture #Cellular & Molecular biology #Cellular assays #Drug development #Drug discovery #Drug targets #Enabling technologies #High Content Screening #High throughput screening #Imaging #Lead discovery #Lead optimisation #PCR #Pharmacology #RNA #Screening #Stem cells #System biology #Systems biology #Toxicology

Dispense and Imaging Assays – Moving towards a more balanced use of both fluorescence and flash luminescent readouts

Dispense and Imaging Assays - Moving towards a more balanced use of both fluorescence and flash luminescent readouts By Dr John Comley Progress towards the uptake and adoption of flash luminescence readouts in screening were the subject of HTStec's recent Dispense & Imaging (D&I) Trends 2007 report. The report suggests… Read More

#Archive

#ADME / Tox #Analysis #Analytical chemistry #Assay development optimisation & technology #Automation / robotics #Business #Cellular & Molecular biology #Chemistry #Clinical trials #Computational chemistry #Drug development #Drug discovery #High Content Screening #High throughput screening #Lead discovery #Lead optimisation #RNA #Screening #Toxicology

The Importance of Liquid Handling Quality Assurance in Drug Discovery

The Importance of Liquid Handling Quality Assurance in Drug Discovery By Dr Nathaniel G Hentz The tug-of-war between quality and productivity is an issue facing all drug discovery companies, competing in a fierce race to bring breakthrough drugs to market before the competition.   With the advance of laboratory automation… Read More

#Archive

#Animal models #Business #Cell therapy #Cellular & Molecular biology #Clinical trials #Drug development #Drug discovery #Drug targets #Gene editing #Gene therapy #Immunology #Lead discovery #Oncology #Regulatory #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology

Advances in Antibody Therapy – A promising new approach to how we treat cancer

Advances in Antibody Therapy - A promising new approach to how we treat cancer By Dr Patrick A Baeuerle Antibodies available today for cancer treatment, while effective, are typically used in combination with standard therapies because their activity as monotherapy is limited. Currently, four conventional antibody products dominate the oncology… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Biochemistry #Biomarkers #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Combinatorial chemistry #Computational chemistry #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #Immunology #In Silico Biology #Isotope labelling #Lead discovery #Mass spectrometry / NMR #Molecular medicine #Oncology #Pharmacogenomics #Pharmacology #Protein chemistry / Proteomics #RNA #Stem cells #System biology #Systems biology #Target validation #Toxicology #Translational #Translational chemistry

Progress in Systems-Based Analysis of Cellular Signalling

Progress in Systems-Based Analysis of Cellular Signalling By Dr Jeffrey A. Radding Drug discovery currently focuses on targeted approaches, relying on validation of the target as a disease driver. However, the underlying biological complexity of disease often frustrates these attempts at therapeutic intervention, resulting in high failure rates due to… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Biochemistry #Business #Cellular & Molecular biology #Cellular assays #Drug development #Drug discovery #Drug targets #Enabling technologies #High Content Screening #High throughput screening #Imaging #Lead discovery #Microfluidics #PCR #RNA #Screening #Stem cells #System biology #Systems biology #Toxicology

Needs and challenges in High Throughput Screening

Needs and challenges in High Throughput Screening By William Downey, Dr Helen Nicely and Dr Lynne Sopchak High throughput screening (HTS) groups face similar challenges as the pharmaceutical and biotechnology industry as a whole faces. HTS groups are looking for ways to improve effectiveness in lead discovery, increase their productivity… Read More

#Archive

#AI / data analytics / healthtech / informatics #Animal models #Assay development optimisation & technology #Automation / robotics #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomics #High throughput screening #Lead discovery #Molecular medicine #Pharmacology #Precision medicine #Preclinical #Protein chemistry / Proteomics #Regenerative Medicine #RNA #Screening #Stem cells #Target validation #Toxicology

Human ES Cell Derived Functional Cells as Tools in Drug Discovery

Human ES Cell Derived Functional Cells as Tools in Drug Discovery By Dr Petter Bjorquist, Dr Peter Sartipy, Dr Raimund Strehl and Dr Johan Hyllner The drug discovery process is extremely-time consuming and expensive. Consequently, novel approaches for these processes and for reducing late-stage attrition are of great value for… Read More

#Archive

#ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Animal models #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Combinatorial chemistry #Computational chemistry #Drug development #Drug discovery #Drug targets #Genetics / genomes #High throughput screening #In Silico Biology #Lead discovery #Lead optimisation #Medicinal chemistry #Metabolomics #Molecular medicine #Organic chemistry #Pathology #Pharmacology #Pharmokinetics #Preclinical #Regulatory #RNA #Screening #Stem cells #System biology #Systems biology #Toxicology

Perspectives for ADMET Integration in the Discovery Process

Perspectives for ADMET Integration in the Discovery Process By Dr Constance Hofer ADMET (ADME/Tox), is a relatively new symbiotic acronym for the investigation of basic compound behaviour in terms of absorption, distribution, metabolism and excretion, combined with assessments of toxicity. The emergence of ADMET instead of ADME reflects the growing… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Automation / robotics #Biomarkers #Business #Cellular & Molecular biology #Clinical trials #Drug development #Drug discovery #Oncology #Regulatory #RNA #Toxicology

The Role of Thorough QT Testing in Managing Drug Development

The Role of Thorough QT Testing in Managing Drug Development By Dr William S. Wheeler With few exceptions, all compounds being submitted to the Food and Drug Administration (FDA) for approval in the United States will require an assessment of QT prolongation, either by a standard Thorough QT/QTc study, or… Read More

#Archive

#Analysis #Automation / robotics #Biomarkers #Business #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Genetics / genomes #Genetics / genomics #Genomics #Lead discovery #Molecular medicine #Pharmacogenomics #Protein chemistry / Proteomics #RNA #Sequencing #System biology #Systems biology #Target validation #Toxicology

Next Generation DNA Sequencing Technologies

Next Generation DNA Sequencing Technologies By Dr Bruce E. Taillon and Brendon Hill Human genetics is the foundation of disease as well as the response to pharmaceutical agents. Today, promising drugs are abandoned due to the lack of significant efficacy in broad patient populations. Recently, blockbuster drugs have been removed… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Biomarkers #Business #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug repositioning #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #Lead discovery #Molecular medicine #Oncology #Pharmacogenomics #Pharmokinetics #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Theranostics #Therapeutics #Toxicology

Industry Strategies on Theranostics: Need for structural alignment

Industry Strategies on Theranostics: Need for structural alignment Dr Rutger O. van Merkerk and Dr Wouter P.C. Boon Theranostics is said to change the way patients will manage their disease. Such a change assumes that diagnostics and therapeutics become increasingly linked based on genetic information. Companies that adhere to this… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Automation / robotics #Biomarkers #Business #Chemistry #Clinical trials #Combinatorial chemistry #Computational chemistry #Drug development #Drug discovery #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Imaging #In Silico Biology #Lead discovery #Lead optimisation #Molecular medicine #PCR #Pharmacology #Protein chemistry / Proteomics #Regulatory #RNA #Screening #System biology #Systems biology #Target validation #Toxicology

Technology, Bane or Bonanza for the Pharmaceutical industry?

Technology, Bane or Bonanza for the Pharmaceutical industry? By Dr Stephen Naylor, Adam W. Culbertson and Dr Stephen J. Valentine Productivity in the pharmaceutical industry has long held well-documented concerns.   While the adoption of new technologies into the drug discovery and development process has often been seen as a… Read More

#Archive